Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Quince Therapeutics, a late-stage biotech company, provided updates on its development pipeline and financial results for Q1 2024. The company is focusing on advancing their lead asset, EryDex, for ataxia-telangiectasia and Duchenne muscular dystrophy. They secured regulatory approvals for their pivotal Phase 3 NEAT clinical trial and are on track for enrollment. The potential market opportunity for their A-T treatment is estimated at over $1 billion globally. Quince is also evaluating other indications for EryDex and exploring strategic partnerships to support their pipeline expansion. Financially, they reported cash reserves of $67.8 million for Q1 2024 and expect to fund operations through 2026.
Quince Therapeutics, Inc. (Nasdaq: QNCX) will present at The Citizens JMP Life Sciences Conference to discuss their innovative drug delivery technology for rare diseases. The presentation by Quince's CEO and CMO will be available via live webcast on May 13, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.